The successful management of invasive fungal infections continues to pose a difficult
challenge to clinicians. As the population of at-risk immunocompromised patients increases …

To evaluate the tolerability and liver safety profiles of the systemic antifungal agents
commonly used for the treatment of invasive fungal infection, we conducted a systematic …

It is important to realize that guidelines cannot always account for individual variation among
patients. They are not intended to supplant physician judgment with respect to particular …

Background. Blood levels of voriconazole, a first line therapy for invasive aspergillosis, may
correlate with adverse events and treatment response. However, no randomized controlled …

Background. Voriconazole is the therapy of choice for aspergillosis and a new treatment
option for candidiasis. Liver disease, age, genetic polymorphism of the cytochrome …

Invasive fungal infection (IFI) is a serious threat after allogeneic hematopoietic cell transplant
(HCT). This multicenter, randomized, double-blind trial compared fluconazole (N= 295) …

Background. Recommended oral voriconazole (VRC) doses are lower than intravenous
doses. Because plasma concentrations impact efficacy and safety of therapy, optimizing …

Twenty-five patients with proven or probable invasive fungal infections (IFIs) who
experienced two or more episodes of voriconazole therapeutic drug monitoring (TDM) at a …

Background. Prospective evaluation of the antifungal drug, voriconazole, is needed to
determine whether drug toxicity correlates with CYP2C19 genotype or serum concentrations …

Introduction: The number of antifungal agents has sharply increased in recent decades.
Antifungals differ in their spectrum of activity, pharmacokinetic/pharmacodynamic properties …